CAR T cells remain during long-term cancer remission

A number of chimeric antigen receptor (CAR) T cell-based therapies are now approved by the FDA for the treatment of cancer. A study published in Nature found that CAR T cells are still present in two patients who remain cancer-free over a decade after they received CAR T cell therapy as part of a cl...

Descripción completa

Detalles Bibliográficos
Autor principal: Barnes, Katharine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053192/
https://www.ncbi.nlm.nih.gov/pubmed/35603282
http://dx.doi.org/10.1038/s43856-022-00092-w
Descripción
Sumario:A number of chimeric antigen receptor (CAR) T cell-based therapies are now approved by the FDA for the treatment of cancer. A study published in Nature found that CAR T cells are still present in two patients who remain cancer-free over a decade after they received CAR T cell therapy as part of a clinical trial.

Ejemplares similares